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Although previous studies have shown that indomethacin
attenuates the dilative effects of nitroglycerin on human
peripheral veins and canine coronary arteries, its ability
to alter the influence of nitroglycerin on coronary blood
flow in human beings is unknown. In 22 patients (16
men and 6 women, aged 47 ± 10 years [mean :t stan-
dard deviationJ) referred for the evaluation of chest pain,
heart rate, systemic arterial pressure, coronary sinus
blood flow (by thermodilution) and coronary vascular
resistance (mean arterial pressure/coronary sinus blood
flow) were measured before and during the administra-
tion of intracoronary saline solution (n = 6, [control
subjects)) or intracoronary nitroglycerin, 100 pg (n =
16). Of these 16 patients, 8 had no pretreatment and the
other 8 received 50 mg of indomethacin orally, 10 and
2 to 3 hours before study.
In the six control subjects, no variable changed with
saline injection. In the eight patients given nitroglycerin
In the open chest dog, indomethacin has been shown to
attenuate the coronary dilative effect of nitroglycerin (I).
In human beings, it has been shown to induce coronary
vasoconstriction (2) and inhibit nitroglycerin's augmenta-
tion of peripheral venous volume and compliance (3). How-
ever , no previously published study has examined the ability
of indomethacin to alter the coronary dilative effect of ni-
troglycerin in human beings. Therefore, the present study
was performed to 1) assess the effect of intracoronary ni-
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without indomethacin pretreatment, heart rate and mean
systemic arterial pressure were changed modestly (72 :t
15 to 74 :t 15 beats/min and 93 :t 9 to 87 :t 13 mm
Hg, respectively, p < 0.05), coronary sinus blood flow
increased by 56 :t 43% (107 :t 72 to 155 :t 78 ml/min,
p < 0.001) and coronary vascular resistance decreased
(1.12 :t 0.50 to 0.66 :t 0.26 mm Hglml per min, p =
0.004). Indomethacin did not attenuate the response to
nitroglycerin (heart rate , 64 ± q to 64 :t 12 beats/min,
p = NS; mean systemic arterial pressure, 96 :t 7 to 92
:t 6 mm Hg, p = 0.008; coronary sinus blood flow, no
:t 22 to 198 :t 59 ml/min, p < 0.001 [average increase
of 78 :t 33%Jand coronary vascular resistance, 0.91 ±
0.25 to 0.51 ± 0.20 mm Hglml per min, p < 0.001).
Thus, intracoronary nitroglycerin causes an increase in
coronary sinus blood flow and adecrease in coronary
vascular resistance, and this effect is not attenuated by
indomethacin.
troglycerin on coronary blood flow and coronary vascular
resistance, and 2) determine whether pretreatment with in-
domethacin attenuates the effect of nitroglycerin on these
variables.
Methods
Patients. Studies were performed in 22 patients (16 men
and 6 women , aged 26 to 68 years) referred for cardiac
catheterization for the evaluation of chest pain. The protocol
was approved by the Human Subjects Review Committee
of the University of Texas Health Science Center, and all
patients gave written informed consent. Nitrates were dis-
continued 12 hours before study. No attempt was made to
control or alter other antianginal medications , but careful
records were maintained of all beta-adrenergic blocking agents
and calcium antagoni sts given within I week of study. The
exper imental protocol was performed with patients in Inc
fasting state after premedication with 10 mg of oral diaze-
pam. All hemodynamic measurements were performed be-
fore the introduction of iodinated contrast material.
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The protocol was performed in 14 patients (9 men and
5 women, aged 48 ± 9 years [mean ± standard deviation])
when they had not received cycle-oxygenase inhibitors for
10 days. In the remaining eight patients (seven men and
one woman, aged 45 ± II years) indomethacin, 50 mg,
was administered orally 10 hours and again 2 to 3 hours
before catheterization.
Experimental protocol. In each patient, a femoral ar-
tery cannula was inserted percutaneously for the measure-
ment of systemic arterial pressure, and heart rate was
determined by electrocardiographic monitoring. A thermo-
dilution catheter (model CCS-7U-90B, Wilton Webster
Laboratories) was advanced to the coronary sinus from a
basilic vein, and its position was verified oximetric ally and
fluoroscopically, Subsequent determinations of coronary sinus
blood flow were performed by the thermodilution technique
(4), and coronary vascular resistance was calculated by di-
viding mean systemic arterial pressure (mm Hg) by coronary
sinus blood flow (mllmin). A Judkins catheter was advanced
from the femoral artery to the ostium of the left coronary
artery.
After catheter placement was completed, systemic arte-
rial pressure, heart rate and coronary sinus blood flow were
measured, and coronary sinus blood was obtained for se-
rologic: measurements. Subsequently, one of two agents was
injected into the coronary artery. In six patients (none of
whom received indomethacin before the study), saline so-
lution was given to demonstrate 1) that an injection of am-
bient temperature caused no change in coronary sinus blood
flow, and 2) that sequential measurements of coronary sinus
blood now performed within several minutes of each other
are highly reproducible. Therefore, these patients served as
control subjects. In the remaining 16 patients (8 who had
and 8 who had not received indomethacin), 100 p.,g of ni-
troglycerin was administered in 25 seconds. Systemic ar-
terial pressure, heart rate and coronary sinus blood flow
were recorded throughout the injection and for 30 seconds
thereafter.
Chemical analyses. The blood specimens for throm-
boxane B2 (the stable metabolite of thromboxane A2) were
drawn into heparinized plastic syringes and transferredquickly
into iced 10 ml tubes containing indomethacin (10 p.,g) and
heparin (l,000 units). They were immediately centrifuged
at 2,000 g for 15 minutes at 4°C. The supernatants were
separated and stored at - 20°C for subsequent analysis.
Thromboxane B2 was measured by radioimmunoassay (5).
Statistical analyses. All results are reported as mean ±
standard deviation. Changes occurring from baseline to re-
peat study within each group (control, nitroglycerin without
indomethacin or nitroglycerin with indomethacin) were
evaluated using a paired t test (6). The three groups were
compared with one another with an analysis of variance.
For all analyses, a probability (p) value of less than 0.05
was considered significant.
Results
Normal saline (control group). For the six patients who
received saline solution, the systemic arterial pressure, heart
rate, coronary sinus blood flow and coronary vascular re-
sistance were similar at baseline and after saline injection
(Table lA). The thromboxane B2 concentrations in coronary
sinus blood averaged 108 ± 78 pg/ml (range 14 to 225).
Subsequent selective coronary arteriography demonstrated
atherosclerotic coronary artery disease (defined as :::::: 70%
luminal diameter narrowing) of one vessel in three patients,
two vessels in one patient and three vessels in two patients.
Four of these patients were maintained on a beta-adrenergic
blocking agent before study, and two were receiving a cal-
cium antagonist.
Intracoronary nitroglycerin without indomethacin.
Of the eight patients given nitroglycerin without indometh-
acin pretreatment, two subsequently were found to have one
vessel coronary artery disease, two had two vessel disease,
three had three vessel disease and one had angiographically
normal coronary arteries. At the time of catheterization, five
were receiving beta-adrenergic blocking agents and four
were receiving a calcium antagonist. The thromboxane B2
concentrations in coronary sinus blood averaged 118 ± 125
pg/ml (range 26 to 345). For these eight patients, nitroglyc-
erin caused a slight decrease in systemic arterial pressure,
an increase in coronary sinus blood flow and a decrease in
coronary vascular resistance (Table IB). On the average,
coronary sinus blood flow increased 56 ± 43% and coronary
vascular resistance decreased 38 ± 12%.
Intracoronary nitroglycerin with indomethacin pre-
treatment. Of the eight patients given nitroglycerin after
indomethacin, two were shown to have one vessel coronary
artery disease, two had two vessel disease, three had three
vessel disease and one had angiographically normal coro-
nary arteries. Three were maintained on a beta-adrenergic
blocking agent before study and six were receiving a calcium
antagonist. The thromboxane B2 concentrations in coronary
sinus blood averaged 6 ± 5 pg/ml (range 0 to 16) (p <
0.001 in comparison with the other two groups). In these
patients, nitroglycerin induced a modest decrease in sys-
temic arterial pressure, an increase in coronary sinus blood
flow and, as a result, a diminution in coronary vascular
resistance (Table lC). Coronary sinus blood flow increased
78 ± 33%, and coronary vascular resistance decreased 45
± 9%; these changes were not significantly different from
the changes that occurred in the eight patients who received
nitroglycerin without indomethacin pretreatment.
Discussion
Effect of indomethacin on nitroglycerin-induced di-
lation of peripheral veins and coronary arteries. Previous
studies (7-10) suggested that nitroglycerin may exert its
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Table 1. Effects of Intracoronary Injection of Normal Saline Solution or Nitroclycerin on Systemic and Coronary
Hemodynamic Measurements
Diseased Before Injection After Injection
Age (yr) Vessels
Case & Sex (no.) HR Mean BP CSBF CVR HR Mean BP CSBF CVR
A. Patients Receiving Normal Saline Solution
I 44M 3 64 94 120 0.78 60 88 126 0.70
2 52F 3 84 115 67 1.72 84 115 66 1.74
3 65M I 84 75 61 1.23 80 72 57 1.26
4 41F I 108 70 153 0.46 108 70 155 0.45
5 43M 2 80 90 174 0.52 80 90 179 0.50
6 46F I 84 97 75 1.29 82 96 79 1.22
Mean 49 84 90 108 1.00 82 89 110 0.98
±SD 8 14 16 48 0.50 15 17 50 0.51
P NS NS NS NS
B. Patients Receiving Nitroglycerin Without Indomethacin
7 56F 2 84 90 56 1.61 88 75 65 1.15
8 63M 0 52 90 146 0.62 56 82 177 0.46
9 47M 3 60 94 81 1.16 64 87 113 0.77
10 44M I 76 110 58 1.90 80 107 138 0.78
II 48M 3 52 80 74 1.08 52 67 114 0.59
12 50F 2 88 90 78 1.15 88 95 155 0.61
13 42M 3 88 88 271 0.32 88 80 328 0.24
14 26M I 76 102 94 1.09 76 100 146 0.68
Mean 47 72 93 107 1.12 74 87 155 0.66
±SD 10 15 9 72 0.50 15 13 78 0.26
P 0.03 0.025 <0.001 0.004
C. Patients Receiving Nitroglycerin After Indomethacin
15 49M 3 76 98 126 0.78 72 95 186 0.51
16 46M 3 60 89 96 0.93 64 87 189 0.46
17 36M 2 84 105 70 1.50 84 97 98 0.99
18 44M 3 52 89 102 0.87 52 90 198 0.45
19 40M I 64 94 126 0.75 68 84 179 0.47
20 27M I 60 90 98 0,92 60 85 182 0.47
21 50F 0 64 97 130 0,75 64 94 242 0.39
22 68M 2 48 106 131 0.81 44 100 306 0.33
Mean 45 64 96 110 0,91 64 92 198 0.51
±SD II 12 7 22 0.25 12 6 59 0.20
P NS 0.008 <0.001 <0.001
BP = blood pressure (mm Hg); CSBF = coronary sinus blood flow (ml/min); CVR = coronary vascular resistance (mm Hg/ml per min); F =
female; HR = heart rate (beats/min); M = male; NS = not significant; p = probability; SO = standard deviation.
peripheral and coronary vasodilative effects by augmenting
the production and release of prostacyclin (a powerful en-
dogenous vasodilator and inhibitor of platelet aggregation
[11,12]) by vascular endothelial cells. Other studies (1,3)
demonstrated that indomethacin (a cyclooxygenase inhibi-
tor) attenuates the hemodynamic effects of nitroglycerin. In
the anesthetized open chest dog, Morcillio et al. (I) showed
that indomethacin alters the dilatory influence of nitroglyc-
erin on coronary arteries. Similarly, Dusen and Fischl (3)
demonstrated in healthy human volunteers that indometh-
acin attenuates nitroglycerin-induced augmentation of vol-
ume and compliance of the peripheral vasculature. In con-
trast, McGregor and Crelinsten (13) recently showed that
indomethacin does not adversely affect exercise capacity or
the clinical response to sublingual nitroglycerin in patients
with angina of effort. However, the effect of indomethacin
on nitroglycerin-induced alterations in coronary blood flow
in human beings has not been assessed previously.
Our data demonstrate that intracoronary nitroglycerin
causes an increase in coronary sinus blood flow in patients
with atherosclerotic coronary artery disease and that the
magnitude of this increase is not influenced by pretreatment
with indomethacin. In the eight patients not given indo-
methacin, nitroglycerin induced an average increase in coro-
nary sinus blood flow of 56 :±: 43%; in those pretreated
with indomethacin, it induced an increase of 78 :±: 33%
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(difference not statistically significant) (Table IB and C).
Similarly, the changes in coronary vascular resistance in-
duced by nitroglycerin were not attenuated by pretreatment
with indomethacin.
Limitations of study. Our study has the following lim-
itations. First, it assessed the effect of nitroglycerin (with
and without indomethacin pretreatment) on total coronary
sinus blood flow and resistance, Because the thermodiluton
catheters used in this study do not allow a measurement of
regional myocardial blood flow, we are unable to speculate
about the effect of indomethacin on nitroglycerin-induced
alterations in regional flow, Second, in the patients who
rece.ved indomethacin, the response of coronary sinus blood
flow to nitroglycerin was not measured before indomethacin
was given and, as a result, each patient did not serve as his
or her own control. Instead we chose to assess the nitro-
glycerin-induced changes in coronary sinus blood flow in
patients pretreated with indomethacin and to compare these
alter ations with those that occurred in subjects not pretreated
witl indomethacin. In those given indomethacin, it is con-
ceivable that nitroglycerin may have caused a greater in-
crease in coronary sinus blood flow than that actually ob-
served if it had been given in the absence of indomethacin.
However, in our opinion, this is unlikely because nitroglyc-
erin mduced a 78 ± 33% average increase in coronary sinus
blood flow in the eight patients pretreated with indorneth-
acir Third, although we did not assess the serum concen-
tration of indomethacin at the time of study, we are confident
that it exerted its desired effect because the concentration
of thromboxane B2 in coronary sinus blood was profoundly
reduced in the eight patients receiving it, indicating that the
dose of indomethacin was sufficient to inhibit cyclo-oxy-
genase activity and block thromboxane production.
Conclusions. Because indomethacin exerts no demon-
strable effect on the coronary vasodilative potency of nitro-
glycerin, it appears unlikely that the vasodilatory effects of
nitroglycerin are mediated through enhanced prostacyclin
production and release. However, this apparent lack of re-
lation between nitroglycerin-induced coronary dilation and
intracoronary prostaglandin alterations requires further study.
Alternatively, nitroglycerin may exert its effects by inducing
the formation of S-nitrosothiols, unstable intermediates that
actvate guanylate cyclase, stimulate cyclic guanosine
monophosphate accumulation and relax vascular smooth
muscle (14). This, too, requires further investigation in pa-
tients with atherosclerotic coronary artery disease because
the alterations in cyclic guanosine monophosphate noted by
Ignarro et al. (14) occurred only with supratherapeutic con-
centrations of nitroglycerin.
We acknowledgethe skilled technical assistance of Sarah Hawkins. Randy
Christian, Nancy Smith and Nayer Elashram, MD.
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